Latest revenue
$377.3M
as of 2026-03-31
Latest net income
$118.4M
as of 2026-03-31
Net margin
31.4%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $6.71B
- Enterprise value
- $6.71B
- P/E (trailing)
- 28.7×
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $103.89
- 52-wk low
- $47.25
- Beta
- —
- Shares out
- 65.1M
5-year trend
What this company does
Item 1. Business Overview We are the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes. We classify our products into three product categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Our Radiopharmaceutical Oncology product helps healthcare professionals (“HCPs”) Find, Fight and Follow cancer. Our Precision Diagnostic products assist HCPs to Find and Follow diseases. Our Strategic Partnerships include biomarkers and digital solutions in support of our partners’ therapeutic development, out-licensing agreements for non-core assets and…
AI summary unavailable — showing raw filing excerpt
Generated from LNTH's filing dated 2026-02-26
Key risks
Item 1A. Risk Factors You should carefully consider the following risks. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that adversely affect our business. These risks could materially affect our business, results of operations or financial condition, cause the trading price of our outstanding common stock to decline materially or cause our actual results to differ materially from those expected or those expressed in any forward-looking statements made by us or on our behalf. See “Cautionary Note Regarding Forward-Looking…
AI summary unavailable — showing raw filing excerpt
Generated from LNTH's filing dated 2026-02-26
Profitability
Gross margin
61.1%
5.2%Operating margin
20.2%
32.3%Net margin
15.2%
25.6%Return on equity
21.4%
25.4%Return on assets
10.5%
33.5%Leverage
Debt / equity
1.04×
27.3%Long-term debt / equity
0.52×
0.4%Debt / assets
51.1%
13.3%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $377.3M | +1.2% | $118.4M | +62.3% | 31.4% |
Q4 2025 2025-12-31 | $406.8M | +4.0% | $54.1M | +558.8% | 13.3% |
Q3 2025 2025-09-30 | $384.0M | +1.4% | $27.8M | -78.8% | 7.2% |
Q2 2025 2025-06-30 | $378.0M | -4.1% | $78.8M | +26.9% | 20.8% |
Q1 2025 2025-03-31 | $372.8M | +0.8% | $72.9M | -44.3% | 19.6% |
Q4 2024 2024-12-31 | $391.1M | — | $-11.8M | — | -3.0% |
Q3 2024 2024-09-30 | $378.7M | +18.4% | $131.1M | -0.7% | 34.6% |
Q2 2024 2024-06-30 | $394.1M | +22.5% | $62.1M | -32.0% | 15.8% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
In Vitro & In Vivo Diagnostic Substances · SIC 2835
Your notes
Keep private notes on LNTH — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$389.8M
Net activity
−$389.8M
Distinct insiders
7
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns LNTH
Institutional value
$2.29B
Total shares held
30.8M
Distinct holders
262
-89 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 8.2M | $620.7M | -83.2K (-1.0%) | Trimmed |
| 2 | VANGUARD PORTFOLIO MANAGEMENT LLC | 3.2M | $240.8M | — | New |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 2.9M | $221.1M | — | New |
| 4 | REINHART PARTNERS, LLC. | 1.6M | $118.7M | +2.3K (+0.1%) | Added |
| 5 | DIMENSIONAL FUND ADVISORS LP | 1.4M | $104.6M | -35.9K (-2.5%) | Trimmed |
| 6 | Swedbank AB | 1.2M | $93.2M | -1.2M (-50.0%) | Trimmed |
| 7 | TD ASSET MANAGEMENT INC | 1.1M | $86.0M | +421.6K (+59.2%) | Added |
| 8 | UBS Group AG | 867.7K | $65.8M | +471.2K (+118.9%) | Added |
| 9 | MACKENZIE FINANCIAL CORP | 714.6K | $54.2M | +56.9K (+8.6%) | Added |
| 10 | JPMORGAN CHASE & CO | 739.5K | $54.0M | +994 (+0.1%) | Added |
| 11 | Polaris Capital Management, LLC | 617.0K | $46.8M | +79.0K (+14.7%) | Added |
| 12 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 486.5K | $36.9M | -13.4K (-2.7%) | Trimmed |
| 13 | Boston Partners | 470.7K | $35.7M | — | New |
| 14 | Bank of New York Mellon Corp | 463.8K | $35.2M | -5.5K (-1.2%) | Trimmed |
| 15 | VANGUARD FIDUCIARY TRUST CO | 459.0K | $34.8M | — | New |
| 16 | WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 399.6K | $30.3M | -122.6K (-23.5%) | Trimmed |
| 17 | Invesco Ltd. | 362.6K | $27.5M | -3.6K (-1.0%) | Trimmed |
| 18 | Voya Investment Management LLC | 337.0K | $25.6M | +296.3K (+728.1%) | Added |
| 19 | BNP PARIBAS FINANCIAL MARKETS | 299.7K | $22.7M | -7.0K (-2.3%) | Trimmed |
| 20 | DEUTSCHE BANK AG\ | 236.9K | $18.0M | +1.6K (+0.7%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once LNTH's latest filing finishes processing.